Understanding how IgM antibodies activate the immune system's complement response
Mechanisms of IgM mediated activation of the complement system
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-11093455
This study is looking at how IgM antibodies, which are the body's first line of defense against infections, work with the immune system to fight off diseases, and it could help create new treatments for conditions like cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11093455 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms by which IgM antibodies, the first type of antibody produced in response to infections, activate the complement system, which is crucial for immune defense. The study employs advanced techniques such as structural mass spectrometry and electron microscopy to analyze how IgM interacts with antigens and initiates immune responses. By preparing and examining various IgM-antigen complexes, the research aims to uncover the structural changes that occur during this activation process. This knowledge could pave the way for developing new biotherapeutics that utilize IgM antibodies for treating diseases, including cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with autoimmune conditions or cancers that may benefit from enhanced antibody-mediated immunity.
Not a fit: Patients who do not have autoimmune diseases or cancers may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that harness IgM antibodies to enhance immune responses against infections and cancers.
How similar studies have performed: While the specific mechanisms of IgM activation are less understood, similar approaches in studying IgG have shown significant success in developing biotherapeutics.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GUTTMAN, MIKLOS — UNIVERSITY OF WASHINGTON
- Study coordinator: GUTTMAN, MIKLOS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy